ANPCY - ANGLE plc

ANGLE plc

Surrey Research Park
10 Nugent Road
Guildford GU2 7AF
United Kingdom
44 14 8334 3434
https://angleplc.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Andrew David William Newland	Founder, CEO & Exec. Director	554.2k	N/A	1962
Mr. Ian Francis Griffiths	CFO, Fin. Director, Company Sec. & Exec. Director	352.9k	N/A	1965
Mr. Martin Cooke	Director of Operations & Regulatory Affairs	N/A	N/A	1969
Mr. Andrew John Holder	Head of Investor Relations	N/A	N/A	1968
Dr. Madeline Repollet	Head of Clinical Laboratories	N/A	N/A	N/A
Ms. Anne-Sophie Pailhes-Jimenez	Head of R&D - ANGLE Europe Ltd.	N/A	N/A	N/A
Mr. Brett Swansiger	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Corporate governance

ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.